A Phase I Clinical Trial Evaluating the Safety and Maximum Tolerated Dose of Axitinib in Combination With Radiotherapy for Advanced Hepatocellular Carcinoma (HCC)
Latest Information Update: 24 Sep 2019
At a glance
- Drugs Axitinib (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- 19 Sep 2019 Status changed from recruiting to completed.
- 19 Sep 2018 Planned End Date changed from 1 Nov 2017 to 1 Nov 2018.
- 19 Sep 2018 Planned primary completion date changed from 1 Nov 2017 to 1 Nov 2018.